AR027037A1 - Compusto y metodo para el tratamiento del dolor - Google Patents
Compusto y metodo para el tratamiento del dolorInfo
- Publication number
- AR027037A1 AR027037A1 ARP000106797A ARP000106797A AR027037A1 AR 027037 A1 AR027037 A1 AR 027037A1 AR P000106797 A ARP000106797 A AR P000106797A AR P000106797 A ARP000106797 A AR P000106797A AR 027037 A1 AR027037 A1 AR 027037A1
- Authority
- AR
- Argentina
- Prior art keywords
- composite
- compound
- pain treatment
- pain
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describe un compuesto, la 7-cloro-4-hidroxi-2-(2cloro-4-metilfenil)-1,2,5,10-tetrahidropirizazino[4,5-b]quinolin-1, 10-diona, las cualesfarmacéuticamente aceptables del mismo, un método para tratar el dolor que comprende la administracion de una c antidad efectiva para mitigar el dolor delcompuesto y composiciones farmacéuticas que contienen el compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17190699P | 1999-12-23 | 1999-12-23 | |
US23678300P | 2000-09-29 | 2000-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027037A1 true AR027037A1 (es) | 2003-03-12 |
Family
ID=26867555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106797A AR027037A1 (es) | 1999-12-23 | 2000-12-20 | Compusto y metodo para el tratamiento del dolor |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1244662B1 (es) |
JP (1) | JP2003519149A (es) |
KR (1) | KR20020062369A (es) |
CN (1) | CN1188413C (es) |
AR (1) | AR027037A1 (es) |
AT (1) | ATE294177T1 (es) |
AU (1) | AU779703B2 (es) |
BG (1) | BG106831A (es) |
BR (1) | BR0016654A (es) |
CA (1) | CA2394888A1 (es) |
CO (1) | CO5271689A1 (es) |
CZ (1) | CZ296877B6 (es) |
DE (1) | DE60019807T2 (es) |
DK (1) | DK1244662T3 (es) |
EE (1) | EE200200350A (es) |
ES (1) | ES2239632T3 (es) |
HK (1) | HK1048811B (es) |
HU (1) | HUP0300313A3 (es) |
IL (1) | IL150208A0 (es) |
IS (1) | IS6427A (es) |
MX (1) | MXPA02006155A (es) |
MY (1) | MY133596A (es) |
NO (1) | NO20022984L (es) |
NZ (1) | NZ519390A (es) |
PL (1) | PL356664A1 (es) |
PT (1) | PT1244662E (es) |
RU (1) | RU2234507C2 (es) |
SK (1) | SK8792002A3 (es) |
WO (1) | WO2001047927A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0403172D0 (sv) * | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | Manufacturing process |
EP1868587A2 (en) * | 2005-04-08 | 2007-12-26 | Abbott Laboratories | Pharmaceutical formulations comprising fenofibric acid and/or its salts |
JP5790533B2 (ja) * | 2012-02-14 | 2015-10-07 | 住友化学株式会社 | フェニルヒドラジン−β−カルボキシレート化合物の精製方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111266A (en) * | 1993-10-22 | 2002-03-10 | Zeneca Ltd | 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
2000
- 2000-12-19 SK SK879-2002A patent/SK8792002A3/sk unknown
- 2000-12-19 EE EEP200200350A patent/EE200200350A/xx unknown
- 2000-12-19 WO PCT/SE2000/002611 patent/WO2001047927A1/en active IP Right Grant
- 2000-12-19 PL PL00356664A patent/PL356664A1/xx not_active Application Discontinuation
- 2000-12-19 DE DE60019807T patent/DE60019807T2/de not_active Expired - Fee Related
- 2000-12-19 BR BR0016654-5A patent/BR0016654A/pt not_active IP Right Cessation
- 2000-12-19 HU HU0300313A patent/HUP0300313A3/hu unknown
- 2000-12-19 CZ CZ20022177A patent/CZ296877B6/cs not_active IP Right Cessation
- 2000-12-19 JP JP2001549397A patent/JP2003519149A/ja active Pending
- 2000-12-19 CA CA002394888A patent/CA2394888A1/en not_active Abandoned
- 2000-12-19 RU RU2002115270/04A patent/RU2234507C2/ru not_active IP Right Cessation
- 2000-12-19 NZ NZ519390A patent/NZ519390A/en unknown
- 2000-12-19 ES ES00987935T patent/ES2239632T3/es not_active Expired - Lifetime
- 2000-12-19 IL IL15020800A patent/IL150208A0/xx unknown
- 2000-12-19 AU AU24203/01A patent/AU779703B2/en not_active Ceased
- 2000-12-19 CN CNB008174318A patent/CN1188413C/zh not_active Expired - Fee Related
- 2000-12-19 KR KR1020027008043A patent/KR20020062369A/ko not_active Application Discontinuation
- 2000-12-19 DK DK00987935T patent/DK1244662T3/da active
- 2000-12-19 EP EP00987935A patent/EP1244662B1/en not_active Expired - Lifetime
- 2000-12-19 AT AT00987935T patent/ATE294177T1/de not_active IP Right Cessation
- 2000-12-19 MX MXPA02006155A patent/MXPA02006155A/es active IP Right Grant
- 2000-12-19 PT PT00987935T patent/PT1244662E/pt unknown
- 2000-12-20 AR ARP000106797A patent/AR027037A1/es not_active Application Discontinuation
- 2000-12-21 MY MYPI20006091A patent/MY133596A/en unknown
- 2000-12-21 CO CO00097100A patent/CO5271689A1/es not_active Application Discontinuation
-
2002
- 2002-06-18 BG BG106831A patent/BG106831A/xx unknown
- 2002-06-19 IS IS6427A patent/IS6427A/is unknown
- 2002-06-20 NO NO20022984A patent/NO20022984L/no not_active Application Discontinuation
-
2003
- 2003-02-07 HK HK03100925.7A patent/HK1048811B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
ECSP083351A (es) | Composiciones farmacéuticas | |
NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
NZ514574A (en) | Novel method of treatment | |
ATE218582T1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
AR021912A1 (es) | Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones | |
UY27208A1 (es) | Una combinación que comprende combretastatina y agentes anticarcinógenos. | |
HUP9901360A2 (hu) | Cimicifuga racemosa-ból származó extraktum alkalmazása | |
KR970061244A (ko) | 치매 치료용 약학 조성물 | |
DE69200711D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung. | |
BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
AR025060A1 (es) | Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa | |
AR027037A1 (es) | Compusto y metodo para el tratamiento del dolor | |
AR019327A1 (es) | Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana | |
AR014082A1 (es) | Concentrado oral de sertralina | |
AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
BR9908838A (pt) | Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite | |
AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica | |
CO5031290A1 (es) | Formulacion lo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |